Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway
暂无分享,去创建一个
P. Musiani | I. Holen | M. Boccadoro | G. Forni | M. Iezzi | C. Riganti | C. Curcio | F. Cavallo | A. Bosìa | F. Pantaleoni | M. Coscia | M. Massaia | E. Quaglino | H. Mönkkönen | H. Mönkkönen
[1] P. Dong,et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. , 2009, The New England journal of medicine.
[2] B. Brüne,et al. Nitric oxide, apoptosis and macrophage polarization during tumor progression. , 2008, Nitric oxide : biology and chemistry.
[3] M. Borrello,et al. Inflammation and cancer: the oncogene-driven connection. , 2008, Cancer letters.
[4] Mark B. Jones,et al. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. , 2008, Journal of the National Cancer Institute.
[5] I. Holen,et al. Exploring the anti-tumour activity of bisphosphonates in early breast cancer. , 2008, Cancer treatment reviews.
[6] T. Curiel. Regulatory T cells and treatment of cancer. , 2008, Current opinion in immunology.
[7] R. Eils,et al. Systemic spread is an early step in breast cancer. , 2008, Cancer cell.
[8] P. Musiani,et al. Antimetastatic activity of a preventive cancer vaccine (Cancer Research (2007) 67, (11037-11044)) , 2007 .
[9] Z. Werb,et al. Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. , 2007, Cancer research.
[10] P. Musiani,et al. Antimetastatic activity of a preventive cancer vaccine. , 2007, Cancer research.
[11] I. Holen,et al. Zoledronic acid-induced IPP/ApppI production in vivo. , 2007, Life sciences.
[12] M. Boccadoro,et al. Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid. , 2007, Blood.
[13] M. Somerfield,et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] A. Sica,et al. Altered macrophage differentiation and immune dysfunction in tumor development. , 2007, The Journal of clinical investigation.
[15] M. Marra,et al. R115777 (Zarnestra®)/Zoledronic acid (Zometa®) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl‐2 and bad phosphorylation , 2007, Journal of cellular physiology.
[16] P. Clézardin,et al. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. , 2007, Journal of the National Cancer Institute.
[17] G. Bieler,et al. Zoledronate inhibits endothelial cell adhesion, migration and survival through the suppression of multiple, prenylation‐dependent signaling pathways , 2007, Journal of Thrombosis and Haemostasis.
[18] M. Rogers,et al. Molecular Mechanisms of Action of Bisphosphonates: Current Status , 2006, Clinical Cancer Research.
[19] P. Betta,et al. Statins revert doxorubicin resistance via nitric oxide in malignant mesothelioma , 2006, International journal of cancer.
[20] E. Regan,et al. Subcellular localization of tyrosine-nitrated proteins is dictated by reactive oxygen species generating enzymes and by proximity to nitric oxide synthase. , 2006, Free radical biology & medicine.
[21] Alberto Mantovani,et al. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. , 2006, European journal of cancer.
[22] H. Tilg,et al. The effect of zoledronic acid on the function and differentiation of myeloid cells. , 2006, Haematologica.
[23] I. Fidler,et al. Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer. , 2005, Cancer research.
[24] S. Sebti,et al. Inhibition of geranylgeranyltransferase I decreases generation of vascular reactive oxygen species and increases vascular nitric oxide production. , 2005, The Journal of surgical research.
[25] M. Boccadoro,et al. Effector γδ T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma , 2005, Leukemia.
[26] I. Holen,et al. Preclinical evidence for the effect of bisphosphonates and cytotoxic drugs on tumor cell invasion , 2005, Anti-cancer drugs.
[27] P. Clézardin. Anti-tumour activity of zoledronic acid. , 2005, Cancer treatment reviews.
[28] H. Wada,et al. Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines. , 2005, Lung cancer.
[29] M. Boccadoro,et al. Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma. , 2005, Leukemia.
[30] Masahiro Inoue,et al. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. , 2004, The Journal of clinical investigation.
[31] F. Aktan. iNOS-mediated nitric oxide production and its regulation. , 2004, Life sciences.
[32] Piero Musiani,et al. Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice. , 2004, Cancer research.
[33] 黒畑 純也. The third-generation bisphosphonate Zoledronate synergistically augments the anti-Ph[+] leukemia activity of imatinib mesylate , 2004 .
[34] C. Montesano,et al. Induction of γδ T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo , 2003 .
[35] G. Forni,et al. α-Galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[36] E. van Marck,et al. Zoledronic Acid Treatment of 5T2MM‐Bearing Mice Inhibits the Development of Myeloma Bone Disease: Evidence for Decreased Osteolysis, Tumor Burden and Angiogenesis, and Increased Survival , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[37] C. Montesano,et al. Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. , 2003, Blood.
[38] Jonathan R. Green. Bisphosphonates in cancer therapy , 2002, Current opinion in oncology.
[39] A. Kral,et al. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models. , 2001, Cancer research.
[40] M. Rogers,et al. Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. , 2001, Bone.
[41] P. Musiani,et al. A light, nontoxic interleukin 12 protocol inhibits HER-2/neu mammary carcinogenesis in BALB/c transgenic mice with established hyperplasia. , 2001, Cancer research.
[42] Kenneth M. Yamada,et al. Dual Stimulation of Ras/Mitogen-Activated Protein Kinase and Rhoa by Cell Adhesion to Fibronectin Supports Growth Factor–Stimulated Cell Cycle Progression , 2000, The Journal of cell biology.
[43] Piero Musiani,et al. DNA Vaccination Against Rat Her-2/Neu p185 More Effectively Inhibits Carcinogenesis Than Transplantable Carcinomas in Transgenic BALB/c Mice1 2 , 2000, The Journal of Immunology.
[44] B. Hillner,et al. American Society of Clinical Oncology Guideline on the Role of Bisphosphonates in Breast Cancer , 2000 .
[45] Barbara Bottazzi,et al. Autocrine Production of IL-10 Mediates Defective IL-12 Production and NF-κB Activation in Tumor-Associated Macrophages1 , 2000, The Journal of Immunology.
[46] B. Hillner,et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] P. Musiani,et al. Analysis of mammary carcinoma onset and progression in HER-2/neu oncogene transgenic mice reveals a lobular origin. , 1999, Laboratory investigation; a journal of technical methods and pathology.
[48] J. Mönkkönen,et al. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. , 1999, Molecular pharmacology.
[49] Piero Musiani,et al. Interleukin 12–mediated Prevention of Spontaneous Mammary Adenocarcinomas in Two Lines of Her-2/neu Transgenic Mice , 1998, The Journal of experimental medicine.
[50] D. Ghigo,et al. Chloroquine stimulates nitric oxide synthesis in murine, porcine, and human endothelial cells. , 1998, The Journal of clinical investigation.
[51] M. Bonneville,et al. Stimulation of human gamma delta T cells by nonpeptidic mycobacterial ligands. , 1994, Science.
[52] D. Treille,et al. Myeloid surface antigen expression in adult acute lymphoblastic leukemia. , 1990, Leukemia.
[53] P. Ricciardi-Castagnoli,et al. Monokine production by microglial cell clones , 1989, European journal of immunology.
[54] J. J. Lucas,et al. Incorporation of mevalonate into dolichol and other isoprenoids during estrogen-induced chick oviduct differentiation. , 1988, Biochimica et biophysica acta.